Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis

Background: Few data exist on how ofatumumab treatment impacts SARS-CoV-2 booster vaccination response. Methods: KYRIOS is an ongoing prospective open-label multicenter study on the response to initial and booster SARS-CoV-2 mRNA vaccination before or during ofatumumab treatment in relapsing MS pati...

Full description

Bibliographic Details
Main Authors: Tjalf Ziemssen, Eugen Schlegel, Marie Groth, Benjamin Ettle, Tobias Bopp
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Vaccines
Subjects:
COVID-19 vaccination
relapsing multiple sclerosis
ofatumumab
neutralizing antibodies
T-cell responses
Online Access:https://www.mdpi.com/2076-393X/11/5/978

Internet

https://www.mdpi.com/2076-393X/11/5/978

Similar Items